Steven David

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

The COSA AM is in Melbourne this November. It's a highlight of the Australian oncology calendar, and I'm looking forward to presenting on oligometastatic breast cancer. Registrations are at bit.ly/3Mwpunk Hoping to see you there! #COSA23

Congrats to Dr. Belle Sasse on this impactful study! 🎉 Collaboration between @MonashHealth & @PeterMacRadOnc shows metastatic breast MDMs changed treatment plans in 28.1% of patients, highlighting their invaluable role in care. 👉 Read: thebreastonline.com/article/S0960-…

🚩 Sharing our latest article: Here we show that dose dense AC-T, radiotherapy & age affects long-term lymphocyte counts post adjuvant #breastcancer treatment ?implications for IO therapy nature.com/articles/s4152… 👏 @J_DixonDouglas @GustaveRoussy @PeterMacRes @BCRFcure

Wonderful summary on #oligometastatic disease and #oligoprogression in #breastcancer by excellent speakers Prue Francis and @drspdavid @BCTrialsANZ #bct2024 Looking forward to AVATAR-2 ⚡️⚡️ @PeterMacRadOnc

Our phenomenal #radonc team!! A superbly productive and energising day of aspirations and strategic planning @PeterMacRadOnc #thefutureisbright 😎 @PeterMacCC @svporceddu

Big thank you to @TROGfightcancer and my supportive supervisor @drspdavid @PeterMacRadOnc for a fantastic opportunity to speak at this year’s ASM #TROG2024 #TROGASM24

The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!

@piet_ost argues the case for SABR in oligometastatic #prostatecancer - a low toxicity intervention. To better select for patients who benefit most, think biomarkers of the future (genomics), and a role for SABR in mCRPC from ARTO trial #pcsm #radonc #SABR2023

Off and running at this year’s #SABR2023 ⁦@PeterMacCC⁩ ⁦@PeterMacRadOnc⁩. Sold out symposium.

Metastatic #breastcancer at #COSA23 . A/Prof Steven David takes the stage to discuss future directions in #oligometastatic breast cancer care. Alongside A/Prof Shom Goel & Dr Stephen Luen (also from @PeterMacCC) & Kerry Patford, breast care nurse. 👏 @drspdavid @COSAoncology

A/Prof Steven David sharing a phase 2 trial of stereotactic #radiotherapy for oligoprogressive ER positive breast #cancer #RANZCR2023

#AVATAR was a standout at ASTRO this year. Kudos for the remarkable effort!

Thanks to the patients and the trial team. AVATAR presented at #ASTRO2023 #radonc @PeterMacRadOnc

Congratulations @drspdavid 👏👏😊 huge amount of work, presented so clearly and with beautiful slides ☺️ @PeterMacRadOnc @PeterMacRes @TROGfightcancer #breastcancer team #ASTRO2023

@drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!

@_ShankarSiva puts on an audiovisual Masterpiece with impressive results, establishing a new standard of care as SABR for inoperable RCC. Bravo ! #sabr #astro23 #petermac

Overall, an important study with promising findings, and I'm proud to have been a member of this team! 17/ cc: @TylerSbrt @_ShankarSiva @MSuppli @PBlanchardMD @ACKoongMDPhD @safaviaa @piet_ost @DrJNaidoo @JahanMohiuddin @MSK_RadOnc